Cerebrovascular Disease Secondary Prevention Smart Management System
Cerebrovascular Disease Secondary Prevention Smart Management System: The continuous post-discharge intervention for patients was conducted using the Cerebrovascular Disease Secondary Prevention Smart Management System. This system, integrated with a WeChat-based applet, records patients' basic information and connects with mobile IoT devices such as blood pressure monitors and glucose meters. This allows patients to self-monitor their risk factors post-discharge. Based on international guidelines, high-level evidence, and the clinical expertise of cerebrovascular specialists, a comprehensive clinical decision-making tree was developed. This serves as the foundation for an AI feedback system that provides intelligent feedback on risk factor control and predicts the risk of recurrence.
Study summary
The purpose of this study is to develop a digital health-based intelligent management system for the secondary prevention of ischemic stroke and to evaluate its effectiveness through a multicenter randomized controlled trial, assessing its health economic value.
Participants will receive usual care after discharge (control group) or be managed with a WeChat-based intelligent management system after discharge (intervention group).
At one year, all patients will undergo face-to-face follow-up to assess clinical events, medication adherence, and the achievement of target risk factor levels.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
1. Age ≥ 18 years.
2. Patients diagnosed with acute ischemic stroke or transient ischemic attack.
3. Time from onset to enrollment ≤ 14 days.
4. Presence of at least one modifiable risk factor (hypertension, diabetes).
5. Ability to independently use a smartphone to complete system tasks upon discharge, or with the assistance of family members.
6. Signed informed consent by the patient or their family members.
Exclusion Criteria:
1. Patients already enrolled in other stroke-related healthcare quality improvement projects or clinical trials.
2. Patients or family members who refuse to sign the informed consent form.
3. Pregnant or breastfeeding women.
Primary outcome measure(s)
Vascular events and all-causes death — From enrollment to 1 year follow-up Vascular and all-cause mortality events were collected for one year post-enrollment through face-to-face follow-ups and patient self-reports. Vascular events included stroke recurrence, transient ischemic attacks, myocardial infarction, vascular interventions or surgeries, and systemic embolism. If a patient experienced both a vascular event and death, only one event was recorded. In cases of multiple vascular events, only the first event was documented.
Risk factor control rate — From enrollment to 1 year follow-up Risk factor control was defined as achieving glycated hemoglobin (HbA1c) ≤7% or blood pressure below the target set at discharge. If a patient had both hypertension and diabetes at enrollment, meeting the criteria for both conditions was considered two achieved targets. If the patient had only hypertension or diabetes at enrollment, meeting the target for the respective condition was considered one achieved target.
Trial sites (3)
Facility
City
Region
Status
Beijing Tsinghua Changgung Hospital
Beijing
Beijing Municipality
Active Not Recruiting
The First Affiliated Hospital of Shihezi University
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.